Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Multiple myeloma
BCMA and GPRC5D CAR-T cells and bispecifics, and what is left after triple-class exposure.
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego · Cancer Research 86 (7_Supplement)
All 7,489 abstracts, including clinical trial (CT) and late-breaking (LB) abstracts, have Cancer Research supplement DOIs in Crossref.
Indexed in Crossref
62 abstracts matching multiple myeloma from the meeting's journal supplement, fetched live from Crossref 2026-11-12 11:12 UTC. This is a keyword search, not the complete abstract book.
- 1893Inhibiting CDK9/13 decreases progression of multiple myeloma and myeloma-induced bone disease in preclinical studies.Tiina E. Kähkönen, Gergana Gababova, Ru Yang, Jie Wen et al.
- 3280Rewiring glutamine metabolism restores osteoblast differentiation in multiple myelomaMumtaz Shirin, Natalya N. Pavlova
- 7352CYLD mediated non-canonical RelB NF-κB transcription axis in multiple myelomaUday Aditya Sarkar, Lalit Kumar
- 7609Emotional functioning and NR3C1 and FKBP5 expression in multiple myeloma.Mark Aaron Fiala, Steven Cole, Judith E. Carroll
- 1636TNF-driven paracrine killing determines the cytotoxic efficacy of Teclistamab in MyelomaAllison Carr, Elise Sintim-Aboagye, Adrian Ting
- 3024Enhancing targeted delivery in multiple myeloma via novel NCI-H929 lipid-extracted-modified nanoliposomesKenny D. Pham, Shivmani Barve, Robert B. Campbell
- 7904Galectin-9 as a glycan-modulating adjuvant to enhance Elotuzumab-mediated immunotherapy in multiple myelomaRajib Kumar Shil, Guenther Koehne, Charles J. Dimitroff
- 7431
- 7122Nanoparticle-mediated restoration of pomalidomide sensitivity in multiple myelomaJoseph Uche Ogbede, Kaiqi Long, Michael S. Rogers, Jinjun Shi et al.
- 4501Targeting the epigenetic adaptor protein menin in multiple myeloma.Emily Gruber, Sree Kumar, Rheana Franich, Tiffany Khong et al.
- 1002Parallel drug development strategies for fibrolamellar hepatocellular carcinoma and proteasome-dependent multiple myelomaShalini Rawat, Najmeh Rahimi, Jared Alderman, Celeste Villasenor et al.
- 2716Machine learning-based screening tool for multiple myeloma detection in chronic kidney disease patients with limited laboratory testing.Wen-Chi Wu, Muh-Hwa Yang, Chih-Yu Yang
- 5721Aldehyde dehydrogenase inhibition as a strategy to overcome drug-refractory multiple myelomaMichael J. Ingling, Robert Chitren, Krishne Gowda, Shantu Amin et al.
- LB220Can dietary calcium prevent myeloma onsetSyed Hassan Mehdi, Dongjoon Lee, Alex Lee, Ha-neui Kim et al.
- 1792Comprehensive identification of factors involved in the resistance mechanism of a novel cereblon modulator in multiple myeloma cellsSho Osawa, Tomofumi Yamamoto, Rina Tamaru, Natsumi Seki et al.
- 277IMV102, an in vivo BCMA-targeting CAR-T therapy, achieves durable tumor control in multiple myeloma models.Yantao Li, Shuangshuang Zhang, Xiaojiang Fan, Zhenggang Jiang et al.
- 1535Preclinical evaluation of allogeneic BCMA/CD70 Dual CAR T cells for high-risk multiple myelomaMark K. O'Dair, David Qu, Duy Nguyen, Kristen Zhang et al.
- 7399Eosinophils promote an immunosuppressive bone marrow microenvironment in multiple myelomaHaley du Bois, Alberto Chaves, Ryan Bishop, Dina Atta et al.
- 5078Sex-specific plasma-immune architectural differences in bone marrow predicts overall survival in multiple myelomaDharini Raghavan, Advait Madabhushi, Amritpal Singh, Tilak Pathak et al.
- 3880Functional high risk multiple myeloma is unified by a highly proliferative signature on gene expression profiling.Hashini Thilakaratne, Jessie Zhao, Daniel Wong, Tiffany Khong et al.
- 5055The association of allostatic load (AL) with diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and progression to multiple myeloma (MM)Mark Aaron Fiala, Qingyuan Tan, Mei Wang, Su-Hsin Chang
- 1847Improve proteasome inhibitor response by targeting NHE6-mediated endosomal-autophagic machaniery in multiple myeloma.Yutong Wang, Liuting Chen, Winston Huang, Jin He et al.
- 5354Extrachromosomal DNA shapes aggressive transcriptional states in multiple myeloma.Hi Eun Jung, Saeam Shin, Yu Ri Kim, Ja Min Byun et al.
- 7309Chronic extracellular acidosis drives metabolic plasticity and adaptive survival in multiple myelomaHua-Ling Chen, Pei-Chu Tsai, Sheng-Chieh Lin, Fang-Yu Tsai et al.
- 3510High-dose FcRH5xCD3 T-cell-engaging bispecific antibody (TCB) overcomes Treg-mediated suppression in-vitro in multiple myelomaKai Lu, Darya Khantakova, Rin Nakamura, Kerstin Trunzer et al.
- 6651Characterizing the risk of infections with T-cell engagers in multiple myeloma.Lindsay Fogel, Harsh Parmar, Shucen Wan, Adolfo Aleman et al.
- 6266Functional Class I, Class II, and nonclassical HLA variation drives lymphoma and myeloma risk in the all of us research program.Lara Sucheston-Campbell, Saanika Tambe, Lian Zuo, Alyssa Clay-Gilmour et al.
- 6358Project CoMMunity: A local learning network deployed to address multiple myeloma care gaps in two communitiesCesar Rodriguez, John T. Mckay, Abdur Rahman Jabir, Alex Lieberman-Cribbin et al.
- 3248Characterization of multiple myeloma genomes with LinkPrep assay enables detection of somatic variation and SV-driven interactions of the 3D genomeLisa Munding, Nathan Becker, Enze Liu, Alexander Fortuna et al.
- 825Bone marrow from acute myeloid leukemia (AML) and multiple myeloma (MM) patients can be used to evaluate target expression and on-target efficacy for novel antibody drug conjugates (ADCs).Aisha Mergaert, Coranna Akdemirbey, Mariah Suchan, Tara Murray et al.
- 1939Oncogenic NSD2 drives Eph-ephrin signaling between myeloma and bone marrow stromal cells.Austin Boese, Lindsey Rosas Togo, Qing Wu, Bethany Kaplan et al.
- 3994Differences in the mutational landscape across race and sex highlight distinct TP53-associated risk in multiple myelomaChidiebube Ugwu, Nneoma Ubah, Muluken Megiso, Angimar Uriepero Palma et al.
- CT253First in India, phase 1/2 study of an indigenously adapted, cost-efficient autologous dual-target BCMA/CD19 CAR T-cell therapy for relapsed or refractory multiple myelomaUday Kumar Surampudi, Prashant Kashinath Bhavar, Partha Pratim Sarma, Rishi Rahangdale et al.
- 7542In vitro and in vivo evaluation of bortezomib using the 5TGM1 cell line and a syngeneic mouse model of multiple myelomaMari I. Suominen, Katja M. Fagerlund, Justyna Zdrojewska, Jukka P. Rissanen et al.
- 1689Next generation ConjuAll BCMA antibody-drug conjugates (ADCs) LCB14-2524 and LCB14-2516 show increased efficacy in preclinical models of multiple myelomaMatthew Sender, Joe Ponte, Stephen Slocum, Yun-Hee Park et al.
- 2405A first-in-class IKZF1/3 degrader antibody conjugate (DAC) as a potential myeloma treatment.Shuai Wu, Jinyu Yang, Mo Dan, Xiwu Hui et al.
- 5535GPRC5D multispecific antibodies: Engineering for affinity, cross-species reactivity, and bi/trispecific engagement in multiple myelomaHayley Roth, Trevor Barnes, Daniel Rogers, Ileine Sanchez et al.
- 3603Implications of multiple myeloma polygenic risk scores (PRS) for MGUSAlyssa Ione Clay-Gilmour, Angelica Macauda, Cristine Allmer, Danelle Moonen et al.
- 1223Spatial transcriptomics identifies a suppressive T-cell excluded tumour microenvironment in extramedullary multiple myeloma.Nicholas E. Bingham, Julie R. Boiko, Daniel C. Jones, Daniel Wong et al.
- 2437A comparative scoring framework for BCMA-, GPRC5D- and CD38-targeted therapies in multiple myelomaKonstantin Chernyshov, Stanislav Kurpe, Maria Kuzmicheva, Kseniia Fede et al.
- 5113Multiple myeloma screening educationKarie Feldman, Diana Basali, Kimberly Bell, Pamela Combs et al.
- 421Kirsten rat sarcoma virus (KRAS) oncoprotein as a new therapeutic target in multiple myeloma.Jeffreay Zonder, Bin Bao, Amro AbouKameel, Sahar Bannoura et al.
- 1279Exploiting Wnt-induced DNA damage repair vulnerability with PARP inhibitors to overcome chemoresistance in multiple myeloma.Kaushlendra Tripathi, Gabriella Santos, Camila Pacocha, Shadika Panta et al.
- 1520Improving BCMA-targeted CAR-T cell therapy of myeloma using TGF-β resistance and inducible production of IL-18Sandhya Rai, Shijing Wang, Bin Sun, Tyce Kearl et al.
- CT254Results of a randomized placebo-controlled phase 2 study of metformin for the prevention of progression of precursor multiple myelomaCatherine R. Marinac, Robert Redd, Adam S. Sperling, Lorenzo Trippa et al.
- 420Targeting proliferating cell nuclear antigen via a miRNA-CSC axis as a new therapeutic approach in multiple myeloma.Jeffrey A. Zonder, Bin Bao, Amro Aboukameel, Sahar F. Bannoura et al.
- 6997Defining mechanisms limiting NK cell function in the multiple myeloma tumor microenvironmentSadia Afrin, Michelle Becker-Hapak, Lyra Morina, Wilbur Song et al.
- 3887Multiple myeloma risk classification of CoMMpass using Consensus Genomic Staging identifies differences between patients with high and low African genetic ancestry.Steven M. Foltz, Chaitanya R. Acharya, Alexander Gout, Yuxin Jin et al.
- 2714Development of a novel Ikaros/Aiolos transcriptional signature and correlation with patient response in multiple myeloma patients treated with CELMoDs.Saleh Tamim, Nicholas Stong, Yan Kai, Diana Jankeel et al.
- 5940Chromosome-level phasing to resolve haplotypes using multiomic data in multiple myeloma reveals complex distal interactions between chromosomes that impacts epigenetic states and gene expressionNathan J. Becker, Enze Liu, J. Zachary Sanborn, Attaya Suvannasankha et al.
- 2597Baseline cfDNA fragmentomics identifies multiple myeloma patients at risk of early progressionDor David Abelman, Jenna Eagles, Aimee Wong, Saumil Shah et al.
- 5504CoMMpass Explorer: An interactive platform to explore clinical and genomic data from newly diagnosed multiple myeloma patients from the landmark CoMMpass observational study.Wanxing Zhang, Chaitanya R. Acharya, Steven M. Foltz, David E. Avigan et al.
- 6475Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapiesChristoph Schaefers, Angelo Jose Guilatco, Sofia Arbelaez, Gabriel Alvares Borges et al.
- 6781First in class catalytic inhibitor of KAT2A/B demonstrates anti-tumor activity in multiple myelomaKristen Jensen-Pergakes, Shawn O'Connell, Sacha Ninkovic, Natalie Miller et al.
- 6467Myeloma cells with therapy-induced senescence-like phenotype are associated with resistance to CAR-T therapySofia Arbelaez, Andre De Menezes Silva Corraes, Gabriel Alvares Borges, Chen Wu et al.
- 3980Non-canonical CAR T cell states correlate with durable therapeutic responses in multiple myeloma patientsKai Wu, Karen Law, Serena Kwek, Marcel Arias-Badia et al.
- 3912NQO1 as a target to overcome therapy resistance in multiple myeloma.Seungbin Han, Christina Verbruggen, Lenka Besse, Shilpa Kurian et al.
- 1067Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistanceBruno Paiva, Peter Voorhees, Patricia T. Greipp, Danielle Sookiasian et al.
- 1598Preclinical efficacy of a bispecific NK cell engager studied using a humanized multiple myeloma mouse modelMari I. Suominen, Katja M. Fagerlund, Mervi Ristola, Justyna Zdrojewska et al.
- CT133First-in-human trial of 225Actinium-DOTA-daratumumab, an alpha-emitting radioimmunotherapy, in patients with daratumumab-refractory multiple myelomaScott Ryan Goldsmith, Vikram Adhikarla, Murali Janakiram, Michael Rosenzweig et al.
- CT103Ciltacabtagene autoleucel in high-risk smoldering myeloma: Results from the CAR-PRISM trialOmar Nadeem, David Cordas dos Santos, Sarah Nikiforow, Kevin DeBraganca et al.
- 888Impact of neighborhood disadvantage, travel distance, and travel time on clinical outcomes of multiple myeloma patients treated with idecabtagene vicleucel.Alicia R. Richards, Jessica Y. Islam, Yu Chen Lin, Ariel F. Grajales-Cruz et al.